keyword
MENU ▼
Read by QxMD icon Read
search

Amisulpride

keyword
https://www.readbyqxmd.com/read/29432503/therapeutic-drug-monitoring-of-atypical-antipsychotics
#1
REVIEW
Anna Emilia Urban, Wiesław Jerzy Cubała
The paper presents an overview and analysis of the results of research on therapeutic ranges of concentrations and receptor occupancy, mainly D2 receptors, in the treatment with some atypical antipsychotic drugs. Amisulpride, aripiprazole, clozapine, quetiapine, olanzapine, risperidone, paliperidone, sertindole, and ziprasidone were taken into account. The benefits of therapeutic drug monitoring to optimize the effectiveness of treatment and avoid side effects or toxicity were shown. The safety of patients, with the possibility to use the lowest effective dose, is an undoubted profit of TDM...
December 30, 2017: Psychiatria Polska
https://www.readbyqxmd.com/read/29430641/comparative-effect-of-antipsychotics-on-risk-of-self-harm-among-patients-with-schizophrenia
#2
C-H Ma, S-S Chang, H-J Tsai, S S-F Gau, I-M Chen, S-C Liao, Y-L Chien, M H Hsieh, C-S Wu
OBJECTIVE: To investigate the association of different antipsychotic treatments with hospitalization due to self-harm among patients with schizophrenia. METHOD: This retrospective cohort study was based on Taiwan's universal health insurance database. Patients aged 15-45 years with a newly diagnosed schizophrenic disorder in 2001-2012 were included. The study outcome was the first hospitalization due to self-harm or undetermined injury after the diagnosis of schizophrenic disorders...
February 11, 2018: Acta Psychiatrica Scandinavica
https://www.readbyqxmd.com/read/29429138/qtc-prolongation-in-short-term-treatment-of-schizophrenia-patients-effects-of-different-antipsychotics-and-genetic-factors
#3
Ilja Spellmann, Matthias A Reinhard, Diana Veverka, Peter Zill, Michael Obermeier, Sandra Dehning, Rebecca Schennach, Norbert Müller, Hans-Jürgen Möller, Michael Riedel, Richard Musil
Antipsychotics are effective in treating schizophrenia but may lead to a higher cardiovascular risk due to QTc prolongation. Besides drugs, genetic and clinical factors may contribute to QTc prolongation. The aim of this study is to examine the effect of candidate genes known for QTc prolongation and their interaction with common antipsychotics. Thus, 199 patients were genotyped for nine polymorphisms in KCNQ1, KCNH2, SCN5A, LOC10537879, LOC101927066, NOS1AP and NUBPL. QTc interval duration was measured before treatment and weekly for 5 weeks while being treated with risperidone, quetiapine, olanzapine, amisulpride, aripiprazole and haloperidol in monotherapy...
February 10, 2018: European Archives of Psychiatry and Clinical Neuroscience
https://www.readbyqxmd.com/read/29406775/response-of-catatonia-to-amisulpride-and-lorazepam-in-an-adolescent-with-schizophenia
#4
Nagihan Cevher Binici, Zehra Topal, Nuran Demir Samurcu, Mehmet Akif Cansız, Uğur Savcı, Yusuf Öztürk, Gonca Özyurt, Ali Evren Tufan
No abstract text is available yet for this article.
February 6, 2018: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/29403138/amisulpride-reexposure-and-tardive-dyskinesia
#5
Ajeet Sidana
To highlight the association between amisulpride and onset of tardive dyskinesia (TD) in patient suffering with psychosis not otherwise specified (NOS), who has already been treated with amisulpride for many years. A 40-year-old female suffering with psychosis NOS since 19 years presented with recurrence of positive symptoms in the form of delusion of persecution, ideas of grandiosity since last 3 months. She was treated with amisulpride up to 400 mg/day and developed involuntary oro-buccal-lingual movement within 2 months of amisulpride therapy...
January 2018: Indian Journal of Psychological Medicine
https://www.readbyqxmd.com/read/29403128/add-on-aripiprazole-for-atypical-antipsychotic-induced-clinically-significant-hyperprolactinemia
#6
Dhanya Raveendranthan, Naren P Rao, Mukund G Rao, Ajish G Mangot, Shivaram Varambally, Muralidharan Kesavan, Ganesan Venkatasubramanian, Bangalore N Gangadhar
Background: Antipsychotic treatment-induced hyperprolactinemia is a highly distressing and disabling side effect for patients. The use of add-on aripiprazole has been identified as a possible treatment strategy in this situation. However, data on prolactin changes with add-on aripiprazole in a real-world naturalistic clinical setting from India are sparse. Materials and Methods: The retrospective chart review was conducted at the specialty metabolic clinic at the National Institute of Mental Health and Neurosciences, Bengaluru, India...
January 2018: Indian Journal of Psychological Medicine
https://www.readbyqxmd.com/read/29368205/antipsychotic-drugs-for-patients-with-schizophrenia-and-predominant-or-prominent-negative-symptoms-a-systematic-review-and-meta-analysis
#7
Marc Krause, Yikang Zhu, Maximilian Huhn, Johannes Schneider-Thoma, Irene Bighelli, Adriani Nikolakopoulou, Stefan Leucht
BACKGROUND: Negative symptoms are the core of schizophrenia, but whether antipsychotics are efficacious for their treatment is unclear. Moreover, there is debate whether patients in relevant trials should have predominant negative symptoms or whether prominent negative symptoms are also acceptable. METHODS: We systematically reviewed randomised, blinded antipsychotic drug trials in patients with schizophrenia and either predominant or prominent negative symptoms (last search Dec 12, 2017)...
January 24, 2018: European Archives of Psychiatry and Clinical Neuroscience
https://www.readbyqxmd.com/read/29251282/dopamine-receptor-specific-contributions-to-the-computation-of-value
#8
Christopher J Burke, Alexander Soutschek, Susanna Weber, Anjali Raja Beharelle, Ernst Fehr, Helene Haker, Philippe N Tobler
Dopamine is thought to play a crucial role in value-based decision making. However, the specific contributions of different dopamine receptor subtypes to the computation of subjective value remain unknown. Here we demonstrate how the balance between D1 and D2 dopamine receptor subtypes shapes subjective value computation during risky decision making. We administered the D2 receptor antagonist amisulpride or placebo before participants made choices between risky options. Compared with placebo, D2 receptor blockade resulted in more frequent choice of higher risk and higher expected value options...
December 18, 2017: Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/29214532/qualitative-and-quantitative-temporal-analysis-of-licit-and-illicit-drugs-in-wastewater-in-australia-using-liquid-chromatography-coupled-to-mass-spectrometry
#9
Richard Bade, Jason M White, Cobus Gerber
The combination of qualitative and quantitative bimonthly analysis of pharmaceuticals and illicit drugs using liquid chromatography coupled to mass spectrometry is presented. A liquid chromatography-quadrupole time of flight instrument equipped with Sequential Window Acquisition of all THeoretical fragment-ion spectra (SWATH) was used to qualitatively screen 346 compounds in influent wastewater from two wastewater treatment plants in South Australia over a 14-month period. A total of 100 compounds were confirmed and/or detected using this strategy, with 61 confirmed in all samples including antidepressants (amitriptyline, dothiepin, doxepin), antipsychotics (amisulpride, clozapine), illicit drugs (cocaine, methamphetamine, amphetamine, 3,4-methylenedioxymethamphetamine (MDMA)), and known drug adulterants (lidocaine and tetramisole)...
December 6, 2017: Analytical and Bioanalytical Chemistry
https://www.readbyqxmd.com/read/29182611/the-differential-effects-of-neuroleptic-drugs-and-pacap-on-the-expression-of-bdnf-mrna-and-protein-in-a-human-glioblastoma-cell-line
#10
Marta Jóźwiak-Bębenista, Magdalena Jasińska-Stroschein, Edward Kowalczyk
Despite numerous studies, the molecular mechanisms underpinning the action of antipsychotic drugs remain not fully understood. It has been suggested that, in addition to the modulation of monoaminergic neurotransmission, antipsychotic drugs can also affect the expression of neurotrophic factors in the brain. The present study examines the effects of a first-generation neuroleptic drug (FGA; haloperidol) and two second-generation neuroleptic drugs (SGAs; olanzapine and amisulpride) on the expression and levels of brain-derived neurotrophic factor (BDNF) in an astrocyte-like T98G glioblastoma cell line...
2017: Acta Neurobiologiae Experimentalis
https://www.readbyqxmd.com/read/29145751/negative-symptoms-and-reward-disturbances-in-schizophrenia-before-and-after-antipsychotic-monotherapy
#11
Mette Ødegaard Nielsen, Egill Rostrup, Brian Villumsen Broberg, Sanne Wulff, Birte Glenthøj
BACKGROUND: Negative symptoms (NS) are a central part of the symptomatology of schizophrenia, which is highly correlated to the functional outcome. Disturbances of the brain reward system are suggested to be central in the pathogenesis of NS by decreasing motivation and hedonic experiences. In this study, we compared reward-related brain activity in patients improving and not improving in NS after treatment with amisulpride. METHODS: Thirty-nine antipsychotic-naive patients and 49 healthy controls completed functional magnetic resonance imaging with a modified monetary incentive delay task...
November 1, 2017: Clinical EEG and Neuroscience: Official Journal of the EEG and Clinical Neuroscience Society (ENCS)
https://www.readbyqxmd.com/read/29130014/a-case-of-probable-amisulpride-induced-mania-after-eight-months-of-therapy
#12
Prakash Thapa, Rajasee Sharma
Development of manic symptoms during treatment with atypical antipsychotics can be a troublesome side effect that has been described with most atypical antipsychotics. However, reports of amisulpride induced mania have been rare. Here, we report the case of an 18-year-old male patient diagnosed with schizophrenia, who developed manic symptoms while on treatment with amisulpride. While previous reports have described occurrence of mania within days to three months of treatment with amisulpride, we report a case where manic symptoms occurred after around eight months of therapy...
2017: Case Reports in Psychiatry
https://www.readbyqxmd.com/read/29069511/negative-symptom-interventions-in-youth-at-risk-of-psychosis-a-systematic-review-and-network-meta-analysis
#13
Daniel J Devoe, Aaron Peterson, Jean Addington
Objective: Youth at clinical high risk (CHR) for psychosis often demonstrate significant negative symptoms, which have been reported to be predictive of conversion to psychosis and a reduced quality of life but treatment options for negative symptoms remain inadequate. Therefore, we conducted a systematic review and network meta-analysis of all intervention studies examining negative symptom outcomes in youth at CHR for psychosis. Method: The authors searched PsycINFO, Medline, Embase, CINAHL, and EBM from inception to December 2016...
October 24, 2017: Schizophrenia Bulletin
https://www.readbyqxmd.com/read/28947383/polymorphism-of-the-snap25-gene-is-associated-with-symptom-improvement-in-schizophrenic-patients-treated-with-amisulpride
#14
Seung-Gul Kang, Ik-Seung Chee, Hun Soo Chang, Kyoung-Sae Na, Kwanghun Lee, Jonghun Lee
Synaptosomal-associated protein 25kDa (SNAP25) is a promising candidate gene related to the treatment response to antipsychotics. Thus, the present study investigated the associations between polymorphisms of SNAP25 and the treatment response to amisulpride in patients with schizophrenia. This study enrolled 154 schizophrenic patients from six university hospitals in South Korea. All patients were assessed with the Positive and Negative Syndrome Scale (PANSS) and the Clinical Global Impression-Severity (CGI-S) scale at baseline and week 6 of treatment...
November 20, 2017: Neuroscience Letters
https://www.readbyqxmd.com/read/28927482/treating-depressive-episodes-or-symptoms-in-patients-with-schizophrenia
#15
Geeske van Rooijen, Jentien Marloes Vermeulen, Henricus Gerardus Ruhé, Lieuwe de Haan
Depressive episodes or symptoms occur frequently in patients with schizophrenia and may have far-reaching consequences. Despite the high prevalence rate and clinical relevance of this comorbidity, knowledge about treatment options is still limited. The aim of this review is to provide an overview of the literature concerning treatment options for depressive episodes or symptoms in schizophrenia. Based on the current evidence, we present a stepwise treatment approach. The first step is to evaluate the current antipsychotic treatment of psychotic symptoms and consider lowering the dosage, since increased blockade of the dopamine D2 receptors may be associated with a worse subjective sense of well-being and dysphoria...
September 20, 2017: CNS Spectrums
https://www.readbyqxmd.com/read/28921163/discriminative-stimulus-properties-of-the-atypical-antipsychotic-amisulpride-comparison-to-its-isomers-and-to-other-benzamide-derivatives-antipsychotic-antidepressant-and-antianxiety-drugs-in-c57bl-6-mice
#16
Timothy J Donahue, Todd M Hillhouse, Kevin A Webster, Richard Young, Eliseu O De Oliveira, Joseph H Porter
RATIONALE: Racemic (RS)-amisulpride (Solian(®)) is an atypical antipsychotic drug used to treat schizophrenia and dysthymia. Blockade of dopamine D2/D3 and/or serotonin 5-HT7 receptors is implicated in its pharmacological effects. While the (S)-amisulpride isomer possesses a robust discriminative cue, discriminative stimulus properties of (RS)-amisulpride have not been evaluated. OBJECTIVES: The present study established (RS)-amisulpride as a discriminative stimulus and assessed amisulpride-like effects of amisulpride stereoisomers, other benzamide derivatives, and antipsychotic, antidepressant, and anxiolytic drugs...
December 2017: Psychopharmacology
https://www.readbyqxmd.com/read/28869006/amisulpride-augmentation-in-clozapine-unresponsive-schizophrenia-amicus-a-double-blind-placebo-controlled-randomised-trial-of-clinical-effectiveness-and-cost-effectiveness
#17
Thomas Re Barnes, Verity C Leeson, Carol Paton, Louise Marston, Linda Davies, William Whittaker, David Osborn, Raj Kumar, Patrick Keown, Rameez Zafar, Khalid Iqbal, Vineet Singh, Pavel Fridrich, Zachary Fitzgerald, Hemant Bagalkote, Peter M Haddad, Mariwan Husni, Tim Amos
BACKGROUND: When treatment-refractory schizophrenia shows an insufficient response to a trial of clozapine, clinicians commonly add a second antipsychotic, despite the lack of robust evidence to justify this practice. OBJECTIVES: The main objectives of the study were to establish the clinical effectiveness and cost-effectiveness of augmentation of clozapine medication with a second antipsychotic, amisulpride, for the management of treatment-resistant schizophrenia...
September 2017: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/28861008/case-of-secondary-tics-associated-with-olanzapine-in-an-adult
#18
Eric W Mills, Lindsay S Shaffer, Fernando S Goes, Akira Sawa, Frederick C Nucifora
Atypical antipsychotic medications, such as risperidone, aripiprazole, and olanzapine, have utility in treating motor tics, particularly in Tourette syndrome. In rare cases, atypical antipsychotic medications have been associated with adult-onset motor tics. Such adverse drug reactions have been documented in response to quetiapine, aripiprazole, and amisulpride. Here, we report, to our knowledge, the first case of adult-onset motor tics related to olanzapine administration.
2017: Frontiers in Psychiatry
https://www.readbyqxmd.com/read/28858444/a-population-approach-to-guide-amisulpride-dose-adjustments-in-older-patients-with-alzheimer-s-disease
#19
Suzanne Reeves, Julie Bertrand, Emma McLachlan, Fabrizia D'Antonio, Stuart Brownings, Akshay Nair, Suki Greaves, Alan Smith, Joel T Dunn, Paul Marsden, Robert Kessler, Hiroyuki Uchida, David Taylor, Robert Howard
OBJECTIVE: We have previously reported high dopamine D2/3 receptor occupancies at low amisulpride concentrations in older people with Alzheimer's disease (AD), during off-label treatment of AD-related psychosis. This post hoc analysis explored pharmacokinetic (concentration) and pharmacodynamic (prolactin, D2/3 occupancy) contributions to symptom reduction and extrapyramidal side effects (EPS) to inform AD-specific dose adjustments. METHODS: Population pharmacokinetic-pharmacodynamic models were developed by combining pharmacokinetic data from a phase 1 study in 20 healthy older people with pharmacokinetic prolactin, [¹⁸F]fallypride D2/3 receptor imaging, and clinical outcome data from 28 older patients prescribed open amisulpride (25-75 mg/d) to treat AD-related psychosis...
July 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/28801850/amisulpride-in-the-prevention-of-nausea-and-vomiting-induced-by-cisplatin-based-chemotherapy-a-dose-escalation-study
#20
Jørn Herrstedt, Yvonne Summers, Gedske Daugaard, Thomas B Christensen, Karin Holmskov, Paul D Taylor, Gabriel M Fox, Alexander Molassiotis
PURPOSE: The purpose of this study was to investigate the antiemetic effect of the dopamine D2- and dopamine D3-receptor antagonist, amisulpride, in patients receiving cisplatin-based chemotherapy. METHODS: This dose-finding, non-comparative study investigated the antiemetic effect and safety of increasing doses (2.5, 7.5 and 20 mg) of amisulpride against acute nausea and vomiting in the period 0-24 h after initiation of cisplatin-based chemotherapy. The 20 mg dose was also investigated in combination with the 5-HT3-receptor antagonist, ondansetron...
August 11, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
keyword
keyword
48025
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"